LATEST ASPIRIN NEWS:
March 2013 - 'The Role of Aspirin and NSAIDs in Cancer Prevention' seminar by NCI Director, Dr Asad Umar (brochure)
March 2013 - ASPREE responds to aspirin-melanoma study in post-menopausal women. (click here to read)
Feb 2013 - The Big Picture on Aspirin - interview with Prof John McNeil.(click here to read)
ASPREE would like to thank the Australian Ageing Agenda for permission to publish the article on our website
Jan 2013 - ASPREE Principal Investigator, Prof John McNeil clarifies aspirin and Age-Related Macular Degeneration (AMD) research (click here)
Jan 2013 - ASPREE response to study of aspirin use and Age-Related Macular Degeneration (click here)
The file '/AUS/UserControls/Custom_ASPREE/AspreePromoVideo.ascx' does not exist.
Nov 2012 - 2013- Sir Gus Nossal lends his support for ASPREE in two Community Service Announcements
ASPREE 30 seconds (video)
ASPREE 15 seconds (video)
Many thanks to Prime, Win and Southern Cross Stations for airing this CSA. Special thanks to Gus for his time and support for the study. (Please let us know if you see this!)
To see more updates go to 'news' or click here
Primary ethics site
Monash University Human Research Ethics Committee (MUHREC)
Secondary ethics sites
1. Royal Australian College of General Practitioners.
2. Human Research Ethics Committee (Tasmania) Network.
3. ACT Health Human Research Ethics Committee.
4. Goulburn Valley Health Ethics & Research Committee
Aspirin may help older people to live well for longer by delaying the onset of illnesses. In fact, previous studies have shown that low dose aspirin:
- Reduces the risk of heart attack, stroke and vascular events in middle aged people
- May help to prevent cognitive decline and forms of cancer such as bowel cancer
However, aspirin is known to have adverse-effects, such as bleeding, that may offset its benefits. Before doctors can know for sure if aspirin is helpful in prolonging healthy life in older people, the benefits must be weighed against the risks.
The ASPREE study, for the first time, will determine whether the potential benefits of aspirin outweigh the risks for people over age 70.
The Trial -
- ASPREE is a randomised, double-blind placebo controlled study
- It involves both males and females, 70 years and older
- Participants are randomly assigned (or randomised) to take either a low-dose aspirin tablet (100mg) or a placebo tablet (dummy pill) for a period of 5 years
- The study will recruit 19,000 healthy participants through regional centres (both in urban and rural locations throughout Australia and the United States)
- Annual follow-ups will involve a number of health, clinical and other measurements click here Any abnormalities will be reported to the participant’s doctor for further assessment